CPIX Stock — Cumberland Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$7.32

Market cap

$109.7M

Cash

$3.9M

Enterprise value

$105.8M

Balance sheet

Cash	$3.9M
Debt	$0.0M
Net cash	$3.9M
Enterprise value	$105.8M
Basic shares	15.0M shares
Fully diluted shares	16.6M shares
Fully diluted market cap	$121.4M
Cash per share	$0.26

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CPIX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 25	Ifetroban Sodium	Phase 2	Idiopathic Pulmonary Fibrosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ifetroban

Phase 2 · Active

Target TPr (thromboxane-prostanoid receptor)

Partnerships Vanderbilt Health: completed Phase 2 solid-tumor metastasis prevention study

Indications

DMD-associated cardiomyopathy (Phase 2)
Systemic sclerosis (SSc) (Phase 2)
Idiopathic pulmonary fibrosis (IPF) (Phase 2)
Cancer metastasis prevention in high-risk solid tumors (Phase 2)
Hepatorenal syndrome (Phase 2)
Portal hypertension (chronic liver disease) (Phase 2)
Aspirin-exacerbated respiratory disease (AERD) (Phase 2)

Status note Lead indication: DMD-associated cardiomyopathy (Orphan Drug + Rare Pediatric Disease + Fast Track designations; End-of-Phase 2 meeting Sep 2025, Type C meeting Jan 2026). Branded commercial portfolio sold to Apotex July 1, 2026; company now focuses on ifetroban development.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ifetroban Sodium
Lead indication	Idiopathic Pulmonary Fibrosis
Lead phase	Phase 2
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05571059	Phase 2	Recruiting	Sponsor	Cumberland Pharmaceuticals	—	Idiopathic Pulmonary Fibrosis	—
NCT02682511	Phase 2	Active, not recruiting	Sponsor	Cumberland Pharmaceuticals	—	Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited	—
NCT06119061	Phase 4	Recruiting	Collaborator	Aaron Cook	—	Subarachnoid Hemorrhage, Aneurysmal	—
NCT07387666	Early Phase 1	Recruiting	Collaborator	University of Texas Southwestern Medical Center	—	Glioblastoma; GBM	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Cumberland Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	503,153	-50,000	0.53%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CPIX — Cumberland Pharmaceuticals Inc.